🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for NF1

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma NCT04166409Phase 3132 sites📍 Birmingham📍 Mesa📍 Phoenix National Cancer Institute (NCI) · Tests: Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration The NF Registry Sponsored by the Children's Tumor Foundation NCT01885767n/a1 site📍 New York The Children's Tumor Foundation A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 NCT06541847Phase 214 sites📍 Birmingham📍 Los Angeles📍 Palo Alto Healx Limited · Tests: HLX-1502 Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) NCT06222203n/a1 site📍 Bethesda National Cancer Institute (NCI) Natural History Study of Patients With Neurofibromatosis Type 2 NCT00598351n/a1 site📍 Bethesda National Institute of Neurological Disorders and Stroke (NI… PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas NCT06961565Phase 15 sites📍 Birmingham📍 St Leonards📍 Melbourne Pasithea Therapeutics Corp. · Tests: PAS-004 Tablets A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia NCT05849662Phase 1, Phase 221 sites📍 Phoenix📍 Los Angeles📍 San Francisco Therapeutic Advances in Childhood Leukemia Consortium · Tests: Trametinib, Azacitidine, Fludarabine, Cytarabine Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence NCT04763109NA1 site📍 Los Angeles Nicole Baca · Tests: Whole-body Magnetic Resonance Imaging MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas NCT07407803Phase 329 sites📍 Hefei📍 Beijing📍 Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ-B3234 capsules, TQ-B3234 placebo Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample PAS-004 in Patients With Advanced Solid Tumors NCT06299839Phase 17 sites📍 Austin📍 Irving📍 San Antonio Pasithea Therapeutics Corp. · Tests: PAS-004 Capsules, PAS-004 Tablets Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy NCT07233408NA1 site📍 Boston Massachusetts General Hospital · Tests: NF1 Educational Videos, Peer Navigator, Letters about NF1 Care Glioma Developmental and HyperActive Ras Tumor (DHART) Board NCT05489783n/a7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study NCT06880991n/a1 site📍 Bethesda National Cancer Institute (NCI) · Tests: Arm 1 GROWing Up With Rare GENEtic Syndromes NCT04463316n/a1 site📍 Rotterdam dr. Laura C. G. de Graaff-Herder · Tests: Retrospective file studies A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) NCT06507748NA2 sites📍 Washington D.C.📍 Bethesda National Cancer Institute (NCI) · Tests: AlgometRx Nociometer(R) Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) NCT07888517n/a26 sites📍 Beijing📍 Changchun📍 Changsha AstraZeneca Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST NCT06735820Phase 1, Phase 22 sites📍 Washington D.C.📍 Dallas AeRang Kim · Tests: APG-115, Selumetinib Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy NCT05180825Phase 225 sites📍 Amiens📍 Angers📍 Besançon University Hospital, Strasbourg, France · Tests: Trametinib, Vinblastine Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... NCT02390752Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TURALIO(R) Familial Investigations of Childhood Cancer Predisposition NCT03050268n/a1 site📍 Memphis St. Jude Children's Research Hospital Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 NCT06188741Phase 215 sites📍 Birmingham📍 Los Angeles📍 Palo Alto University of Alabama at Birmingham · Tests: Selumetinib Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) NCT04374305Phase 26 sites📍 Los Angeles📍 Miami📍 Indianopolis Scott R. Plotkin, MD, PhD · Tests: Brigatinib, Neratinib, Retifanlimab, Bevacizumab Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas NCT06381570EARLY Phase 11 site📍 Toronto Daniel Morgenstern · Tests: Tovorafenib, Vinblastine Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas NCT05253131Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: Selumetinib + ZEN-3694 ± Durvalumab Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). NCT06159166Phase 1, Phase 21 site📍 Baltimore Johns Hopkins University · Tests: Mirdametinib RASopathy Biorepository NCT04395495n/a1 site📍 Cincinnati Children's Hospital Medical Center, Cincinnati Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors NCT03454035Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Ulixertinib, Palbociclib Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 NCT03893643n/a1 site📍 Nice Centre Hospitalier Universitaire de Nice · Tests: no intervention
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy